VAM
CORT icon

Verity Asset Management’s Corcept Therapeutics CORT Stock Holding History

Verity Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,211
Closed -$234K – 209
2023
Q4 		$234K Buy
+7,211
New +$198K 0.15% 160

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Verity Asset Management's CORT Position: Q1 2024 in Review

Verity Asset Management sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 7,211 shares — an estimated $234K sold.

Verity Asset Management first reported a position in CORT in Q4 2023 and held it in 1 quarter. The position peaked at $234K in Q4 2023. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

  • Verity Asset Management reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Verity Asset Management sold 7,211 Corcept Therapeutics shares in Q1 2024, an estimated $234K.
  • Verity Asset Management first reported a position in Corcept Therapeutics in Q4 2023 and held it in 1 quarter.
  • Verity Asset Management's Corcept Therapeutics position peaked at $234K in Q4 2023.
  • 287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on Verity Asset Management's 13F filing for Q1 2024, filed 28 May 2024.